MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC lowered its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 95.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,911 shares of the company's stock after selling 82,864 shares during the period. Schonfeld Strategic Advisors LLC's holdings in MoonLake Immunotherapeutics were worth $212,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Birchview Capital LP acquired a new position in MoonLake Immunotherapeutics in the 4th quarter valued at about $217,000. KLP Kapitalforvaltning AS acquired a new position in MoonLake Immunotherapeutics in the 4th quarter valued at about $244,000. PEAK6 LLC acquired a new position in MoonLake Immunotherapeutics in the 4th quarter valued at about $271,000. Mariner LLC acquired a new position in MoonLake Immunotherapeutics in the 4th quarter valued at about $272,000. Finally, Barclays PLC increased its position in MoonLake Immunotherapeutics by 1,269.2% in the 3rd quarter. Barclays PLC now owns 5,641 shares of the company's stock valued at $283,000 after acquiring an additional 5,229 shares during the period. Institutional investors and hedge funds own 93.85% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on MLTX shares. HC Wainwright restated a "buy" rating and issued a $100.00 price target on shares of MoonLake Immunotherapeutics in a research report on Thursday, February 27th. Wedbush reiterated an "outperform" rating and set a $80.00 target price (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday. Needham & Company LLC reiterated a "buy" rating and set a $66.00 target price on shares of MoonLake Immunotherapeutics in a research report on Tuesday. The Goldman Sachs Group dropped their target price on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating on the stock in a research report on Thursday, February 27th. Finally, Royal Bank of Canada initiated coverage on MoonLake Immunotherapeutics in a research report on Tuesday, March 18th. They set an "outperform" rating and a $67.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, MoonLake Immunotherapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $81.67.

MoonLake Immunotherapeutics Trading Down 0.1%

Shares of NASDAQ:MLTX traded down $0.04 during trading on Friday, hitting $37.62. 351,510 shares of the stock were exchanged, compared to its average volume of 356,542. The company has a fifty day moving average price of $38.40 and a two-hundred day moving average price of $44.73. The company has a market cap of $2.41 billion, a PE ratio of -29.16 and a beta of 1.31. MoonLake Immunotherapeutics has a 12-month low of $31.42 and a 12-month high of $58.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.13. During the same period in the previous year, the business posted ($0.22) EPS. Equities research analysts anticipate that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current fiscal year.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.